Autres langues enVVeno Medical Corporation

Actions

NVNO

US29415J1060

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
5 ^USD	0,00%		-1,96%	-2,72%

08/05	EnVVeno Medical Corporation annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/04	EnVVeno Medical Corporation annonce que des données supplémentaires sur l'efficacité de l'étude pivot VenoValve aux États-Unis seront présentées lors du 46e symposium annuel de Charing Cross, le 24 avril 2024.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium	25/04
New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the 46th Annual Charing Cross Symposium on April 24, 2024	17/04
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	16/04
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer	10/04
EnVVeno Medical : Corporate Presentation	10/04
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	09/04
EnVVeno Medical : Corporate Presentation	03/04
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting	07/03
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	06/03
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	06/03
EnVVeno Medical : Corporate Presentation	04/03
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	01/03
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024	21/02
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium	15/12
EnVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	17/11
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	16/11
EnVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update	27/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues enVVeno Medical Corporation

Actions

NVNO

US29415J1060

Autres langues

Filtres